ProCE Banner Activity

Phase II EVOKE-02: First-line Sacituzumab Govitecan + Pembrolizumab in Metastatic NSCLC

Slideset Download
Conference Coverage

In this preliminary analysis, first-line sacituzumab govitecan plus pembrolizumab achieved an ORR of 69% and 44% in patients with metastatic NSCLC with PD-L1 TPS ≥50% and PD-L1 TPS <50%, respectively, and a 6-month duration of response rate of 88% in both groups.

Released: September 20, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc